EUVIMEDEUVIMED entdecken
Übersichtsarbeit

5-HT 1A Agonists for levodopa-induced Dyskinesia in Parkinson’s Disease

Jawad Al-Kassmy iD, Christine Sun, Philippe Huot iD

Neurodegenerative Disease Management · 2023

DOI: 10.2217/nmt-2022-0039 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neurodegenerative Disease Management, 2023. Verfasst von Jawad Al-Kassmy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Royal College of Surgeons in Ireland, School of Medicine, Dublin, Ireland. Hauptthemen laut MEDLINE: Parkinson Disease, Dyskinesia, Drug-Induced. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 77 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Levodopa is the most effective agent for treating the symptoms of Parkinson's disease (PD). However, levodopa-induced dyskinesia remains a significant complication that manifests after few years of treatment, for which therapeutic options remain limited. Several agonists of the serotonin type 1A (5-HT1A) receptor with varying levels of efficacy and interaction at other sites, have been tested in the clinic. Clinical trials testing 5-HT1A agonists have yielded inconsistent results in alleviating dyskinesia, especially that the antidyskinetic benefit observed was often accompanied by an adverse effect on motor function. In this article, we summarize and analyze the various clinical trials performed with 5-HT1A agonists in PD patients with dyskinesia and offer perspectives on the future of this class of agents in PD. After prolonged treatment with levodopa, patients with Parkinson's disease might start to experience abnormal involuntary movements, called ‘dyskinesias’. These abnormal movements may be difficult to cope with since they can occur for several hours during the day and can hamper the quality of life. A potential approach to reduce the severity of dyskinesia, which has been the focus of extensive research, consists of stimulating a target inside the brain called the 5-HT1A receptor. Several drugs harbouring this mechanism of action have been tested in clinical studies. Here, we provide an overview of these clinical studies and discuss their results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDyskinesia, Drug-InducedHumansLevodopaSerotoninSerotonin 5-HT1 Receptor AgonistsAntiparkinson Agents

Stichwörter der Autor:innen

5-HT1A agonistsParkinson's diseasearipiprazolebefiradolbuspironedyskinesialevodopapardoprunoxsarizotantandospirone

Substanzen

LevodopaSerotoninSerotonin 5-HT1 Receptor AgonistsAntiparkinson Agents

Autor:innen und Institutionen

  • Royal College of Surgeons in Ireland, School of Medicine, Dublin, Ireland.
  • Neurodegenerative Disease Group, Montreal Neurological Institute-Hospital (The Neuro), Montreal, QC, H3A 2B4, Canada.
  • Movement Disorder Clinic, Division of Neurology, Department of Neurosciences, McGill University Health Centre, Montreal, QC, H3A 2B4, Canada.
  • Department of Neurology & Neurosurgery, McGill University, Montreal, QC, H3A 2B4, Canada.

ORCID-Profile: Jawad Al-Kassmy, Philippe Huot

Zitieren

APA

Al-Kassmy, J., Sun, C., & Huot, P. (2023). 5-HT 1A Agonists for levodopa-induced Dyskinesia in Parkinson’s Disease. Neurodegenerative Disease Management. https://doi.org/10.2217/nmt-2022-0039

Vancouver

Al-Kassmy J, Sun C, Huot P. 5-HT 1A Agonists for levodopa-induced Dyskinesia in Parkinson’s Disease. Neurodegenerative Disease Management. 2023. doi:10.2217/nmt-2022-0039

BibTeX
@article{AlKassmy2023,
  author = {Al-Kassmy, Jawad and Sun, Christine and Huot, Philippe},
  title = {5-HT 1A Agonists for levodopa-induced Dyskinesia in Parkinson’s Disease},
  journal = {Neurodegenerative Disease Management},
  year = {2023},
  doi = {10.2217/nmt-2022-0039}
}
Kostenlos starten →